SciELO - Scientific Electronic Library Online

 
vol.18 número2Nueva generación de Vacunas Conjugadas Antimeningococica: Fundamentos y Posibilidades a escala MundialEl ácido siálico N-acetilado es inmunogénico e induce anticuerpos protectores contra Neisseria meningitidis índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Vaccimonitor

versión impresa ISSN 1025-028Xversión On-line ISSN 1025-0298

Resumen

P. SAFADI, Marcos Aurelio. Conjugated vaccines against serogroup A, C, W-135 and Y disease. Vaccimonitor [online]. 2009, vol.18, n.2, pp.61-62. ISSN 1025-028X.

Review the current evidence on available and candidate quadrivalent meningococcal conjugate vaccines. Methods: A comprehensive overview of data on the currently available A-C-W135-Y meningococcal vaccine and the results of late stage development of novel quadrivalent candidate vaccines were reviewed. Conclusions: Licensure of highly effective meningococcal C conjugate vaccines represented an enormous progress in the possibility of controlling meningococcal C disease. The unpredictable changing serogroup epidemiology of meningococcal disease emphasizes the need of developing combination conjugate vaccines, containing more than one meningococcal polysaccharide, to broaden protection against the disease. A quadrivalent meningococcal vaccine (A-C-W135-Y) conjugated to diphtheria toxoid is available only in United States and Canada for use in persons 2-55 years of age. However, in infants (the age group with the highest incidence rates of disease) the vaccine proved to be not immunogenic and is therefore not licensed for use in children younger than 2 years.A novel tetravalent meningococcal vaccine (A-C-W135-Y) conjugated to a non-toxic diphtheria mutant toxin (CRM-197) is being evaluated in Phase III trials and has demonstrated to be immunogenic and well tolerated in all age groups, including infants, representing, at last, a real possibility of a broader protection against meningococcal disease.

Palabras clave : Neisseria meningitidis; meningococcal disease; conjugate meningococcal vaccines.

        · texto en Inglés     · Inglés ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons